Accounts filed on 31-08-2017

Accounts filed on 31-08-2017

IMMUNOPHARMA CONSULTING LTD - Company Information

Print Friendly Version

06617668falseresearch and development on biotechnology2016-09-012017-08-31http://www.companieshouse.gov.uk/2016-08-31http://www.companieshouse.gov.uk/pt:ShareCapital2016-08-31http://www.companieshouse.gov.uk/cd:Director12016-09-012017-08-31http://www.companieshouse.gov.uk/pt:ShareCapital2017-08-31http://www.companieshouse.gov.uk/cd:Director22016-09-012017-08-31http://www.companieshouse.gov.uk/cd:Director32016-09-012017-08-31http://www.companieshouse.gov.uk/cd:OrdinaryShareClass12016-09-012017-08-31http://www.companieshouse.gov.uk/cd:RegisteredOffice2016-09-012017-08-31http://www.companieshouse.gov.uk/cd:AuditExemptWithAccountantsReport2016-09-012017-08-31http://www.companieshouse.gov.uk/pt:CurrentFinancialInstruments2017-08-31http://www.companieshouse.gov.uk/pt:CurrentFinancialInstruments2016-08-31http://www.companieshouse.gov.uk/2016-09-012017-08-31http://www.companieshouse.gov.uk/2016-08-31http://www.companieshouse.gov.uk/cd:FRS1022016-09-012017-08-31http://www.companieshouse.gov.uk/2017-08-31http://www.companieshouse.gov.uk/cd:FullAccounts2016-09-012017-08-31http://www.companieshouse.gov.uk/cd:PrivateLimitedCompanyLtd2016-09-012017-08-31iso4217:GBPxbrli:sharesxbrli:pure
Registered number: 06617668
IMMUNOPHARMA CONSULTING LTD
ACCOUNTS
FOR THE YEAR ENDED 31/08/2017
Prepared By:
LHM ACCOUNTANTS
Incorporated Financial Accountants
20 Westlands Way
Oxted
Surrey
RH8 0ND
IMMUNOPHARMA CONSULTING LTD
ACCOUNTS
FOR THE YEAR ENDED 31/08/2017
DIRECTORS
Mrs A E Crowe
Mr J S Crowe
Mr J Crowe
SECRETARY
P K Manster
REGISTERED OFFICE
20 WESTLANDS WAY
OXTED
SURREY
RH8 0ND
COMPANY DETAILS
Private company limited by shares registered in EW - England and Wales, registered number 06617668
BANKERS
National Westminster Bank Plc
ACCOUNTANTS
LHM ACCOUNTANTS
Incorporated Financial Accountants
20 Westlands Way
Oxted
Surrey
RH8 0ND
IMMUNOPHARMA CONSULTING LTD
ACCOUNTS
FOR THEYEARENDED31/08/2017
CONTENTS
Page
Directors' Report-
Accountants' Report-
Statement Of Comprehensive Income-
Balance Sheet3
Notes To The Accounts4
The following do not form part of the statutory financial statements:
Trading And Profit And Loss Account-
Profit And Loss Account Summaries-
IMMUNOPHARMA CONSULTING LTD
BALANCE SHEET AT 31/08/2017
20172016
Notes££
CURRENT ASSETS
Debtors2-12
Cash at bank and in hand2,7903,324
2,7903,336
CREDITORS: Amounts falling due within one year34,3233,291
NET CURRENT (LIABILITIES) / ASSETS(1,533)45
TOTAL ASSETS LESS CURRENT LIABILITIES(1,533)45
CAPITAL AND RESERVES
Called up share capital5100100
Profit and loss account(1,633)(55)
SHAREHOLDERS' FUNDS(1,533)45
For the year ending 31/08/2017 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors have decided not to deliver to the registrar a copy of the company's profit and loss account.
Approved by the board on 10/04/2018 and signed on their behalf by
.............................
Mr J S Crowe
Director
IMMUNOPHARMA CONSULTING LTD
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31/08/2017
1. ACCOUNTING POLICIES
1a. Basis Of Accounting
The accounts have been prepared under the historical cost convention.
The accounts have been prepared in accordance with FRS102 - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006 .
2. DEBTORS 20172016
££
Amounts falling due within one year
Prepayments-12
-12
3. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
20172016
££
Directors current account3,9432,827
Accruals380464
4,3233,291
4. EMPLOYEES
20172016
No.No.
5. SHARE CAPITAL 20172016
££
Allotted, issued and fully paid:
100 Ordinary shares of £1 each100100
100100